BMS-986278
- Generic Name
- BMS-986278
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31N5O5
- CAS Number
- 2170126-74-4
- Unique Ingredient Identifier
- 4UN9AOU6G8
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT06746402
- Locations
- 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States
🇺🇸Local Institution - 0002, San Antonio, Texas, United States
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
- Conditions
- Kidney Failure, ChronicHealthy VolunteersRenal Impairment
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT06723535
- Locations
- 🇺🇸
Clinical Pharmacology Of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Advanced Pharma CR, LLC, Miami, Florida, United States
A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT06715683
- Locations
- 🇺🇸
Anaheim Clinical Trials (ACT), Anaheim, California, United States
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 71
- Registration Number
- NCT06568458
- Locations
- 🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 37
- Registration Number
- NCT06425198
- Locations
- 🇺🇸
Local Institution - 0002, Tampa, Florida, United States
🇺🇸Local Institution - 0001, Miami Lakes, Florida, United States
🇺🇸Local Institution - 0003, Orlando, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
- Conditions
- Progressive Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1092
- Registration Number
- NCT06025578
- Locations
- 🇨🇳
Local Institution - 0424, Suzhou Shi, Jiangsu, China
🇧🇪Vzw Az Groeninge, Kortrijk, Belgium
🇵🇱Local Institution - 0187, Lodz, Poland
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1185
- Registration Number
- NCT06003426
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Local Institution - 0179, Jasper, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 37
- Registration Number
- NCT05985590
- Locations
- 🇨🇦
Local Institution - 0002, Québec, Quebec, Canada
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT05932303
- Locations
- 🇨🇦
Local Institution - 0001, Québec, CA, Canada
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05805904
- Locations
- 🇨🇳
Local Institution - 0001, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.